DNMT3A mutations and clinical features in Chinese patients with acute myeloid leukemia

  • Quanyi Lu1Email author,

    Affiliated with

    • Yamei Chen1,

      Affiliated with

      • Hang Wang2 and

        Affiliated with

        • Zhipeng Li1

          Affiliated with

          Cancer Cell International201313:1

          DOI: 10.1186/1475-2867-13-1

          Received: 24 September 2012

          Accepted: 8 January 2013

          Published: 11 January 2013

          Abstract

          Mutations in DNA methyltransferase 3A (DNMT3A) gene were recently demonstrated in acute myeloid leukemia(AML). Approximately 20% patients with AML carry DNMT3A gene mutations and was associated with a poor clinical outcome. but its clinical implications in Chinese AML patients are largely unknown. We analyzed 101 adult AML patients in china and found 14 patients (13.9%) harboring this mutation. 9 patient with M5, 2 patients with M1, 2patient with M2 and 1 patient with M3. We identified 11 missense mutation,2 nonsense and 30 bp deletion encompassing DNMT3A. The most common of them was predicted to affect 882Arg(in 4 patients). Double mutations were detected in two cases.10 of 33(43.5%). DNMT3A mutations occurred more frequently in older (age > 50y,p < 0.05) and the outcome is too badly for these patients. We concluded that DNMT3A mutations are highly recurrent in AML and is associated with distinct clinical and biologic characteristics and seems to be a useful as a prognostic marker.

          Keywords

          DNMT3A Acute myeloid leukemia Gene mutations

          Background

          Acute Myeloid Leukemia (AML) is a heterogeneous malignancy that can be classified by morphological, cytogenetic and molecular genetic criteria, Currently, cytogenetic analysis at diagnosis allows for risk-stratification of AML into a useful prognostic marker and intermediate risk [1], To some extent, Treatment protocols are adapted in an attempt to improve survival and decrease treatment-related toxicity. Unfortunately, prognostic implications have not been reliably established for AML in the intermediate risk category. In recent years, molecular analysis has identified novel markers with prognostic relevance in this diverse group. For example, AML with internal tandem duplication (ITD) in the fms-like tyrosine- kinase-3 gene (FLT3) carries a poor prognosis [2, 3]. Molecular studies have pinpointed recurrent somatic mutations in NPM1, CEBPα, TET2,MLL-PTD and fusion proteins such as PML-RARα and CBFB-MYH11, which characterize specific types of AML [4].

          The human DNA methyltransferase gene (DNMT1,DNMT3A and DNMT3B) encode enzymes which catalyze the addition of a methyl group to the fifth position of cytosine,generating 5 methylcytosine, by this mechanism, the DNA methyltransferase mediate the downregulation of target gene via the methylation of upstream CPG islands. Gene mutation in DNA methyltransferase which alter enzyme function have now been described in acute leukemia, Yamashita et al. reported [5] 4.1% somatic mutation of DNA methyltransferase (DNMT3A) at amino-acid Arg882 in leukemia, Later Ley [6] et al. found 22.1% DNMT3A mutations in adult normal karyotype AML genome and Chen SJ also discovered gene mutations in DNMT3A in patients with M5 (20.5%) and with 13.6% of M4 subtype [7]. those results above indicated that DNMT3A mutations were independently and significantly associated with decreased survival in adult AML. in order to analyze the influence of DNMT3A mutation on the prognosis and survival of AML. In this study, RNA from bone marrow cells of untreated AML patients from the Chinese patients were examined by using PCR and sequence analysis, simultaneously chromosome examination and immunophenotype were also performed.

          Method

          Patients and samples

          There were 101 patients aged 16–76 years with AML in this study, those were newly diagnosed AML which were classified according to French-American-British(FAB) classification system, including M0(n = 2),M1(n = 4), M2(n = 41), M3(n = 25), M4(n = 6),M5(n = 21), M6(n = 2). All of them were diagnosed and treated in the Zhongshan Hospital of Xiamen University from July 2008 to Dec 2010. Bone marrow(BM) aspirates or peripheral blood(PB WBC > 50 × 109) sample were collected at the first visit and in accordance with guidelines from the ethics committee of the hospital.

          Cytogenetic analysis

          Bone marrow cells were harvested directly before chemotherapy according to the study [8] , the metaphase chromosomes were banded by the G-banding techniques and karyotyped according to the International System for Human Cytogenetic Nomenclature.

          Immunophenotyping

          A panel of monoclonal antibodies to myeloid-associated antigens including CD13, CD14, CD33, as well as lymphoid-associated antigens including CD2, CD5, CD7, CD19, CD20, and lineage nonspecific antigens HLA-DR, CD34 were used to characterize the phenotypes of the leukemia cell with Epics XL4 flow cytometer (Beckman Coulter, America).

          RNA preparation

          Total RNA was isolated using RNAprep pure Blood Kit (Tiangen Biotech, China), according to the manufacturer’s instructions,followed by treatment with RNase-free DNaseI to remove contaminating genomic DNA. The RNA was dissolved in RNase-free H2O, checked for purify and concentration with ND-1000 UV–vis Spectrophotometer (Nanodrop Technologies, USA) and stored at -80°C until to be used.

          Reverse transcription PCR(RT-PCR)

          Reverse transcription was performed with T3 Thermocycle (Biometra, Germany), total RNA (2 μg) was mixed with 10 mmol dNTPs and 25 pmol random primers (TOYOBO, Japan), incubated at 65°C for 5 minutes, chilled immediately on ice, followed by addition of 20 U RNase inhibitor, 1 RT buffer, 100 U MMLV reverse transcriptase (Sangon, China) and RNase-free water to make up a volume of 20 μl. RT reaction was incubated at: 37°C 10 minutes; 42°C 60 minutes; 70°C 10 min. Resultant complementary DNA (cDNA) was diluted with 180 μl ddH2O (10 ng/ μl RNA equivalent) and was stored at -20°C.

          Mutation analysis

          The DNMT3A was amplified by 2 pairs of primers and sequenced by the same ones. The sequences of these PCR and sequencing primers are F1: 5’-GCCACCAGAAGAAGAGAAGAATCC-3’,R1: 5’-CTCTTCTGGGTGCTGATACTTCT-3’,F4: 5’-CTCGCCTCCAAAGACCACG-3’,R3: 5’-TTCTCCGCTGTGCTCTTCC-3’.

          The reference sequence was NM_022552.3 for mRNA. In every 25 μL of PCR reaction, there were 1 SSP buffer (67 mM Tris–HCl, 16 mM (NH4)2SO4, 0.01% Tween 20, pH 8.8), 0.2 mM dNTPs, 2.5 mM MgCl2, 0.4 uM each tagged primer, 0.5 U TaqHS DNA polymerase (Takara, Japan), and 5 μl of cDNA. The amplification was performed in a Thermal Cycler PCR instrument (Bioer, China) under the following conditions: 95°C 3 minutes; 10 cycles of touchdown PCR, 95°C 20 seconds, 65°C -60°C (decreased by 0.5°C per cycle) 20 seconds, 72°C 90 seconds;30 cycles of 95°C 20 seconds, 60°C 20 seconds, 72°C 90 seconds and finally,72°C 7 min.The PCR products were verified by electrophoresis and sequencing. Clone the DNA fragments with overlap peak into pMD18-T vector (Takara, Japan) and sequencing.When the mutations were not obvious because of location near the primers,sequencing from the other direction was done to solve this issue.

          Statistical analysis

          The discrete variables of patients with and without gene mutation were compared using the χ2 tests, but if the theoretical frequency was smaller than 5,correction for continuity was used All statistical analyses were performed with SPSS 16.0 software(SPSS Inc).

          Results

          DNMT3A mutations

          In my study, 101 samples from new diagnostic AML were detected by PCR amplification of entire coding region of DNMT3A, the detection rate of DNMT3A mutations in AML patients was 13.9%(14/101), including 2 patients of M1, 2 patients of M2,1 patient of M3 and 9 patients of M5(42.9%). (Table1) .the type of mutations was 11 missense, 2 nonsense and 1 deletion mutations.respectively. single nucleotide variations included 2645 G > A(Arg882His), 914 G > A(nonsense), 2096 G > A(Gly699Asp), 2501C > T(Thr834IIe), 55C > T(Arg19Trp), 2202C > A(Phe734Leu) and 2644 C > T(Arg882Cys).(,Fig-1) The most common mutations are predicted to affect amino- acid Arg882 (in 6 patients) and Thr834(in 2 patients).We also detected a 30 bp deletion according to sequencing (Figure 1, patient 40). Double point mutation was also detected in 2 patient (Figure 2).DNMT3A mutation (2645 G > A) was found in BM sample of the old patient with M5, this is the same with that of Ewalt reported (Figure 1 patient 77) [9].
          http://static-content.springer.com/image/art%3A10.1186%2F1475-2867-13-1/MediaObjects/12935_2012_396_Fig1_HTML.jpg
          Figure 1

          Sequencing results for patient 7(2645 G > A), patient 19(914 G > A), patient 22 (2645 G > A), patient 38(2906 G > A), patient40 (30 bp del 2502-2531 bp) and patient 47(2501 C > T), Patient 40 harbors a 30 bp deletion and shows a overlap peak.

          http://static-content.springer.com/image/art%3A10.1186%2F1475-2867-13-1/MediaObjects/12935_2012_396_Fig2_HTML.jpg
          Figure 2

          Sequencing results for patient 89, the double point DNMT3A mutation was K: 1906 G > A,L:2191 T > C.

          Table 1

          Clinical features of the Patients with DMNT3A mutations

          No

          Age

          sex

          FAB

          Cytogenetics

          WBC X10^9/L

          CD33+/CD34+

          DNMT3A

          Chemo-response

          result

          7

          65

          F

          M1

          normal

          36.6

          6%/92%

          2645 G > A

          CR

          Dead(12 M)

          19

          72

          M

          M2

          normal

          57.2

          99%/32%

          914 G > A

          No

          Dead(6 M)

          22

          55

          M

          M5

          normal

          112.9

          99%/16%

          2645 G > A

          CR

          Alive(SCT)

          38

          58

          F

          M5

          t(6;9)

          12.1

          56%/55%

          2096 G > A

          CR

          Dead(10 M)

          40

          56

          F

          M2

          inv(9)

          15

          20%/82%

          30 bp del 2502-2531

          CR

          Dead(SCT)

          47

          31

          F

          M5

          del(13)

          1.5

          95%/27%

          2501 C > T

          N0

          Dead(3 M)

          48

          20

          F

          M5

          normal

          30.4

          4.5%/71%

          2501 C > T

          N0

          Dead(3 M)

          53

          53

          F

          M3

          t(4;17)

          7.9

          82%/1.6%

          55 C > T

          CR

          Alive

          56

          54

          F

          M5

          normal

          2.19

          95%/28%

          2202 C > A

          CR

          Relapse(6 M)

          68

          52

          M

          M5

          normal

          28.8

          97%/42%

          2644 C > T

          No

          Dead(6 M)

          77

          76

          M

          M5

          normal

          67

          No

          2645 G > A Arg882His

          CR

          Dead(13 M)

          89

          76

          M

          M1

          normal

          17.3

          CD13 CD34

          1906 G > A 2191 T > C

          NR

          Dead(3 M)

          94

          61

          F

          M5

          normal

          132

          CD7CD13CD33

          2141C > G

          NO

          Dead(1 M)

          100

          46

          M

          M5

          normal

          4.5

          CD13CD34

          1792C > T 2375 G > A

          NR

          Dead(1 M)

          CR Complete remission, No no chemotherapy, NR not remission, M month.

          Clinical features of DMNT3A mutation positive patients

          Of the mutated patients, AML-M5 subtype had higher DNMT3A mutation rate than those with other subtype. Cytogenetic data showed that 10 cases with DNMT3A mutation was normal karyotypes AML patients (71.45%,p > 0.05). No DNMT3A mutations were found in AML samples with cytogenetic findings associated with a favorable (except 1 patient with M3). In all of positive patients, 8 patients were female (57.1%, p > 0.05), 11 patients were older than 50 years (78.6%, p < 0.05). we also discovered that DNMT3A mutations were associated with high expression of CD33 or CD34, After having been treated by induction chemotherapy, all patients achieved complete hematological remission(76.5%), but 4 patients refused to receive chemotherapy, after 12 monthes follow up, only 2 patients were alive including 1 M3 patient.

          Discussion

          Epigenetic mechanisms play a crucial role in regulation of gene expression and DNA methylation catalyzed by specific DNA methyltransferase and DNMTs is an important epigenetic control of gene expression and the maintenance of genome integrity. Many DNMTs appear to be present in human and have a different role in establishing and maintaining the DNA methylation pattern including DNMT1, DNMT2, DNMT3A, DNMT3B and DNMT3L [10, 11]. DNMT1 is the primary enzyme responsible for copping methylation patterns after DNA replication while DNMT2 does not methylate DNA but instead methylates small RNA,. DNMT3A and DNMT3B are paralogous enzymes responsible for de novo DNA cytosine methylation. DNMT3L plays a key role in allowing DNA methylation during the maturation of germ [12]. Mouse studies showed that DNMT is required for hematopoietic stem cell self renewal, regulation of proliferation and normal myeloid and lymphoid differentiation. By contrast, deletion of DNMT3A and DNMT3B in mouse hematopoietic stem cells impaired stem cell self renewal, the frequent DNMT3A mutations may be an parts of pathogenesis in acute myeloid leukemia [13].

          In this study, we report the frequency of DNMT3A mutations in patients with de novo AML and their Clinical features compared to the patients without DMNT3A mutations. We sequenced all coding exon of DNMT3A using DNA from leukemia cells and identified 14 heterozygous mutations (13.9%). Amino acid R882, located in the methyltransferase domain of DNMT3A, was the most common mutation site. Our results showed that the rate of DNMT3A gene mutations in Chinese AML patient is more common and AML-M5 was more higher than other type(9/21) the alterations of Arg882 are also the most frequent mutation in Chinese AML patients. We also found one AML-M3 patient who carried t(4; 17) chromosomal abnormality carry DNMT3A gene mutation and this is not reported by other papers [6, 7].

          Our results indicated that most of patients(11/14) with DNMT3A mutation died of leukemia after 6 months treatment, two patient were alive due to allogeneic stem cell transplant and AML-M3 type. The last one was one relapse. Although it is unclear if DNMT3A mutation can affect survival of AML patient, this fact was accord with concept that DNMT3A mutation could be a dependent factor on AML patients. In concurrence with other reporters, there was no significant association between DNMT3A mutations and sex, high WBC or increased blast percentage in the bone marrow at diagnosis. But the high expression of CD33 or CD34 on AML cells was very common., DNMT3A mutation were found in patients above 50 years of age, this is agreement with previous studies. Although DNMT3A gene mutation was almost never found in AML-M3 subtype, this patient carried t(4; 17) chromosomal abnormality and PML-RARα fusion gene, it may be associated with a poor prognosis for no-classical acute promyelocytic leukemia.

          To conclude, it seems that DNMT3A mutations are consistently present in approximately 10% of AML cases, the role of DNMT3A mutations on leukemogenesis was still unclear. Future studies will help to illuminate the pathogenesis of AML, we need to develop a method of quick determination of the whole gene mutations and evaluate the influence of DNMT3A mutation on treatment response and survival in a larger sample.

          Declarations

          Acknowledgment

          We want to thank Dr Jiangning Zhao, Dr Jiasheng Hu,they provided blood or bone marrow sample and medical care for those patients at Zhongshan Hospital of Xiamen University.

          This work was partially supported by the “985” Program of Medical College of Xiamen University.

          Authors’ Affiliations

          (1)
          Department of Haematology, Zhongshan Hospital of Xiamen University
          (2)
          Department of Biomedical Sciences and the Key Laboratory of the Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University

          References

          1. Tara K, Gregory DW, Chen Y: Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2009, 2:23.View Article
          2. Levis M, Small D: FLT3 ITDoes matter in leukemia. Leukemia 2003, 17:1738–1752.PubMedView Article
          3. Gilliland DG, Griffin JD: The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100:1532–1542.PubMedView Article
          4. Tefferi A: Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010,24(6):1128–38.PubMedView Article
          5. Yamashita Y, Yuan J, Suetake I: Array-based genomic resequencing of human leukemia. Oncogene 2010, 29:3723–3731.PubMedView Article
          6. Ley TJ, Ding L, Walter MJ: DNMT3A Mutations in Acute Myeloid Leukemia. N Engl J Med 2010, 363:2460–2461.View Article
          7. Yan XJ, Xu J, Gu ZH: Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011,13(4):309–315.View Article
          8. Tien HF, Wang CH, Lin MT: Correlation of cytogenetic results with immunophenotype, genetype, clinical features, and ras mutation in acute myeloid leukemia: a study of 235 Chinese patients in Taiwan. Cancer Genet Cytogenet 1995, 84:60–68.PubMedView Article
          9. Ewalt M, Galili NG, Mumtaz M: DNMT3A mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer J 2011,1(3):e9.PubMedView Article
          10. Jaenisch R, Bird A: Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003, 33:245–254.PubMedView Article
          11. Ling Y, Sankpal UT Robertson AK: Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucleic Acids Res 2004, 32:598–610.PubMedView Article
          12. Tang M, Xu W, Wang Q: DNMT and its Epigenetic Regulation for Lung Cancer Therapy. Curr Genomics 2009, 10:336–52.PubMedView Article
          13. Trowbridge JJ, Snow JW, Kim J: DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 2009,2(4):442–449.View Article

          Copyright

          © Lu et al.; licensee BioMed Central Ltd. 2013

          This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

          Advertisement